Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000987 · ClinicalTrials.gov registry record · Phase 2
Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT01000987 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 44 participants.
The verdict
NCT01000987, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is the examine the effect of varenicline on cognition to a high dose (0.08 g/dL) of alcohol (vs. placebo alcohol) over the ascending and descending limb of the blood alcohol curve.
Interventions
- DRUG placebo
- DRUG varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2009-10 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01000987
The ClinicalTrials.gov registry entry for NCT01000987 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01000987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01000987 about?
NCT01000987 is a clinical study titled "Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders". The purpose of this study is the examine the effect of varenicline on cognition to a high dose (0.08 g/dL) of alcohol (vs. placebo alcohol) over the ascending and descending limb of the blood alcohol curve.
What is the current status of trial NCT01000987?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2009-10. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01000987?
The interventions under investigation include: placebo (DRUG), varenicline (DRUG).
Who is sponsoring clinical trial NCT01000987?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.